| | The young founder of the biotech who vowed to remake the blood-analysis business was a billionaire on paper, but her promises never materialized. Now she is settling claims brought by the Securities and Exchange Commission, subject to court approval. Under an agreement with the SEC, without admitting guilt, she will pay a $500,000 penalty, be barred from serving as an officer or director of a public company for 10 years and return 18.9 million shares she amassed during the alleged fraud.
| FOR MORE ON THIS STORY, GO TO: |
|
| |
